Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangadhar, Tara C., Hwu, Wen-Jen, Postow, Michael A., Hamid, Omid, Daud, Adil, Dronca, Roxana, Joseph, Richard, O’Day, Steven J., Hodi, F.S., Pavlick, Anna C., Kluger, Harriet, Oxborough, Romina P., Yang, Aiming, Gazdoiu, Mihaela, Kush, Debra A., Ebbinghaus, Scot, Salama, April K.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Basic Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647109/
https://www.ncbi.nlm.nih.gov/pubmed/29028788
http://dx.doi.org/10.1097/CJI.0000000000000186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647109/
https://www.ncbi.nlm.nih.gov/pubmed/29028788
http://dx.doi.org/10.1097/CJI.0000000000000186

Ejemplares similares